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Abstract: BACKGROUND DEPOSEIN (NCT01645839) was a randomized open-label phase III study
to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metas-
tasis (LM), a common manifestation of breast cancer. METHODS Patients with newly diagnosed LM
defined by tumor cells in the cerebrospinal fluid or combination of clinical and neuroimaging signs of LM
were randomized to receive systemic therapy alone (control group) or systemic therapy plus intrathecal
liposomal cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the
primary endpoint. RESULTS Thirty-seven and 36 patients were assigned to the control and the exper-
imental groups. Median number of liposomal cytarabine injections in the experimental group was five
(range 1-20). Focal radiotherapy was performed in six (16%) and three (8%) patients in the control and
experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 months (95% confi-
dence interval (CI) 1.3-3.1) in the control versus 3.8 months (95% CI 2.3-6.8) in the experimental group
(hazard ratio 0.61, 95% CI 0.38-0.98) (P=0.04). Seventy-one patients have died. Median overall survival
was 4.0 months (95% CI 2.2-6.3) in the control versus 7.3 months (95% CI 3.9-9.6) in the experimental
group (hazard ratio 0.85, 95% CI 0.53-1.36) (P=0.51). Serious adverse events were reported in 22 and
30 patients, respectively. Quality of life until progression did not differ between groups. CONCLU-
SION The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS.
Confirmatory trials with optimized patient selection criteria and more active drugs may be required to
demonstrate a survival benefit from intrathecal pharmacotherapy.
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Background: DEPOSEIN (NCT01645839) was a randomized open-label phase III 
study to explore the role of intrathecal chemotherapy in patients with newly diagnosed 
leptomeningeal metastasis (LM), a common manifestation of breast cancer. 
Methods: Patients with newly diagnosed LM defined by tumor cells in the 
cerebrospinal fluid or combination of clinical and neuroimaging signs of LM were randomized 
to receive systemic therapy alone (control group) or systemic therapy plus intrathecal liposomal 
cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the 
primary endpoint. 
Results: Thirty-seven and 36 patients were assigned to the control and the experimental 
groups. Median number of liposomal cytarabine injections in the experimental group was five 
(range 1-20). Focal radiotherapy was performed in six (16%) and three (8%) patients in the 
control and experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 
months (95% confidence interval (CI) 1.3-3.1) in the control versus 3.8 months (95% CI 2.3-
6.8) in the experimental group (hazard ratio 0.61, 95% CI 0.38-0.98) (P=0.04). Seventy-one 
patients have died. Median overall survival was 4.0 months (95% CI 2.2-6.3) in the control 
versus 7.3 months (95% CI 3.9-9.6) in the experimental group (hazard ratio 0.85, 95% CI 0.53-
1.36) (P=0.51). Serious adverse events were reported in 22 and 30 patients, respectively. 
Quality of life until progression did not differ between groups. 
Conclusion: The addition of intrathecal liposomal cytarabine to systemic treatment 
improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and 






































































































































brain, cerebrospinal, depocyte, neoplastic, meningitis  
 
KEY POINTS  
 Leptomeningeal metastasis (LM) is an advanced stage manifestation of breast cancer. 
 First randomized trial showing a clinical benefit of intrathecal chemotherapy in LM. 
 
IMPORTANCE OF THE STUDY  
Patients with leptomeningeal metastases (LM) are treated in a highly variable fashion. 
DEPOSEIN is a randomized open-label phase III study to explore the addition of intrathecal 
liposomal cytarabine to systemic therapy for the treatment of newly diagnosed leptomeningeal 
metastasis from breast cancer. The DEPOSEIN study shows that, compared to systemic 
chemotherapy alone, the combination of intrathecal chemotherapy with systemic chemotherapy 
prolongs leptomeningeal disease-related progression-free survival. Quality of life until 
progression did not differ between groups, and, surprisingly, this local treatment prolongs 
overall survival by trend in a preplanned analysis in the adjusted ITT population. No differences 
in quality of life were observed between groups although patients in the experimental group had more 
intensive treatment. DEPOSEIN thus confirms a role for intrathecal pharmacotherapy at least in 
subsets of LM patients. A larger confirmatory trial with optimized patient selection criteria may be 




































































































































Leptomeningeal metastasis (LM) commonly represents a manifestation of advanced 
cancer. It affected 8% of patients with metastatic cancer already prior to 1978 1 and is seen most 
often with breast cancer, lung cancer and melanoma. Prognosis remains poor with an overall 
survival (OS) around 4 months in breast cancer patients with LM (Table S1) 2, 3, 4, 5, 6. The main 
goals of LM treatment are to maintain neurological function and quality of life and to prolong 
OS 7. Only five randomized trials have been performed in LM from solid tumors 8, 9, 10, 11, 12, all 
published more than 10 years ago and criticized for methodological limitations 13. Four trials 
included patients with LM from different primary tumors, compared different intrathecal 
chemotherapy regimens, and observed no major differences except for longer time to 
neurological progression with liposomal cytarabine compared with methotrexate in one trial 10. 
The only trial comparing intrathecal therapy with no intrathecal therapy 11 revealed no benefit 
from intrathecal methotrexate. However, response evaluation was based on clinical 
examination only, a high rate of ventricular device complications with 18% reservoir revisions 
was observed, likely negatively affecting outcome in the experimental arm, and the trial was 
stopped prematurely for poor accrual. Thus, a role of intrathecal chemotherapy in LM from 
solid cancers remained unproven. Yet, a recent survey indicated widespread use of this 
treatment modality across Europe 14. Methotrexate, cytarabine and thiotepa are available for 
intrathecal chemotherapy in most European countries and commonly given twice weekly. 
Liposomal cytarabine has a prolonged half-life, allowing for fewer administrations, every 14 
days, and was therefore chosen as the experimental intervention in the DEPOSEIN trial. Its 
purpose was to determine whether intrathecal chemotherapy is of value in the treatment of LM 




































































































































PATIENTS AND METHODS 
Study Design and Participants 
DEPOSEIN (NCT01645839) was a phase III randomized open label study which 
compared systemic treatment alone (control group) to systemic treatment combined with 
intrathecal liposomal cytarabine (experimental group) in patients with newly diagnosed LM 
from breast cancer. The primary aim was to demonstrate superior LM-related progression-free 
survival (LM-PFS) in the experimental group. Secondary endpoints included overall PFS, OS, 
response to treatment, safety, and benefit-risk ratio using the quality-adjusted time without 
symptoms of disease or toxicity (Q-TWiST) approach 15. Exploratory objectives included 
quality of life (QoL) and determination of prognostic factors. 
The study was performed at 5 centers across France. Eligible patients were 18 years of 
age or older, female, had histologically confirmed breast cancer and newly diagnosed LM based 
on the presence of malignant cells in the cerebrospinal fluid (CSF) or the combination of typical 
clinical symptoms and signs and magnetic resonance imaging (MRI) findings. Meningeal 
nodules had to be less than 5 mm in diameter if no focal radiotherapy was planned, but could 
be larger if focal radiotherapy was planned. Irradiated nodules were not used as target lesions 
to define response. Patients had to have an Eastern Cooperative Oncology Group performance 
status (ECOG-PS) score between 0 and 2, be candidates for systemic therapy, and have a life 
expectancy of at least 2 months. Brain metastases were allowed if asymptomatic and not 
considered to require whole brain radiotherapy. Prior whole brain radiotherapy for brain 
metastases or focal radiotherapy to spinal lesions was allowed, but prior craniospinal 
radiotherapy was not. No prior intrathecal chemotherapy or prior systemic treatment with high-
dose cytarabine or methotrexate was allowed. Patients with ventriculoperitoneal shunts were 


































































































































approved by the ethics committees and competent authorities of all participating centers. The 
study was conducted in accordance with the ethical principles of the Declaration of Helsinki 
and Good Clinical Practice Guidelines.  
 
Randomization and Masking 
Patients were randomly assigned to systemic treatment alone or systemic treatment plus 
intrathecal liposomal cytarabine chemotherapy. Randomization (1:1) was performed centrally 
by Oscar Lambret Cancer Centre Research Unit Staff using blocks of six patients, without 
stratification criteria. Neither investigators nor patients were masked to treatment allocation. 
 
Interventions 
Baseline assessment included clinical evaluation including weight, Eastern Cooperative 
Oncology Group (ECOG) performance status, Medical Research Council (MRC) scale, general 
examination, neurological evaluation (Table S2), medical history, current medications, blood 
analysis with hematology, electrolytes, albumin, renal and hepatic functions, CSF cytological 
and biochemical analysis, standardized cerebrospinal MRI (Table S3), extra-central nervous 
system (CNS) evaluation (chest-abdominal-pelvic CT or PET scans), cognitive testing using 
the Montreal cognitive assessment (MoCA) 16, and health-related quality-of-life (HRQOL) 
questionnaires: generic EORTC QLQ-C30 in combination with the QLQ-BN20 brain-cancer 
specific module and the QLQ-C15-PAL module for palliative care. Table S4 summarizes the 
schedule of assessments. Clinical evaluations were foreseen every 14±2 days for 2 months and 
then every 28±5 days. Cerebrospinal MRI was scheduled every two months. 
All patients received systemic treatment selected by the treating physician prior to 
randomization according to molecular tumor characteristics, prior lines of treatments, and 


































































































































liposomal cytarabine 50 mg every 14 days for two months (five injections) followed by monthly 
injections of 50 mg until progression, unacceptable toxicity or for up to one year. Oral steroids 
(5-6 mg equivalent dexamethasone) were recommended for five consecutive days from the day 
of liposomal cytarabine injection to prevent chemical meningitis. In case of severe toxicity, the 
dose of cytarabine could be reduced to 25 mg. Intrathecal chemotherapy was initiated via the 
lumbar route, but the intraventricular route was encouraged. 
  
Outcome Measurements 
The primary endpoint was LM-PFS, defined as the time between randomization and first 
evidence of LM progression, based on clinical or imaging findings assessed by the treating 
center, or death from any cause. Secondary efficacy endpoints included LM-related response 
rate defined by neurological clinical evaluation, MRI or CSF analysis (Tables S5-S8), overall 
PFS, and overall survival (OS). In brief, absence or presence of diffuse or focal contrast 
enhancement, nodules, cortical infiltration, parenchymal extension, and hydrocephalus were 
captured. Nodules were rated as 0-5 mm, 5-10 mm, or more than 10 mm diameter. Complete 
response required the disappearance of all contrast-enhancing lesions and no evidence of new 
lesions. Partial response required a reduction of at least 30% of the sum of the 2 largest 
diameters for measurable lesions, no progression of non-measurable lesions, and no evidence 
of new lesions. Increase of at least 20% of the largest diameter for measurable targets, 
appearance of new leptomeningeal lesions, or progression of non-measurable lesions 
constituted progression. 
 
All survival endpoints were computed from randomization. All adverse events (AE) 
were categorized by MedRA preferred term name and system organ class and graded according 


































































































































whole study period. A grade equal to or higher than 3 was classified as severe. Death occurring 




A previous phase II trial in LM from various solid cancers had revealed a median time 
to neurological progression of 60 days 10. When the protocol was designed, a doubling of LM-
related PFS in the experimental arm was considered clinically meaningful. To show a difference 
of 30 days in LM-PFS with a hazard ratio (HR) of 0.50, bilateral alpha=5%, beta=20%, accrual 
of 7 years, and follow-up of at least 6 months, 66 events had to be observed. Considering the 
hypothesis of an exponential distribution of survival, the LM-PFS rates at 3 months were 
estimated at 12.5% and 35% in the two groups. To take into account a drop-out rate of 20%, 80 




All randomized patients were included in the intent-to-treat (ITT) analysis. The per-
protocol (PP) analysis excluded patients who did not fulfill the inclusion criteria and patients 
who did not start systemic treatment for reasons other than progression, patients in the 
experimental group who did not start intrathecal treatment for reasons other than progression, 
and control group patients treated with intrathecal liposomal cytarabine prior to further 
progression (Figure 1). LM-PFS (main endpoint), overall PFS, and OS were estimated by the 
Kaplan-Meier method from the date of randomization. 
Cox models were used to estimate the HR ratio associated with the treatment effect 


































































































































of the scaled Schoenfeld residuals. Pre-specified sensitivity analyses were performed adjusting 
for ECOG-PS (0 versus 1 versus two or more) at LM diagnosis, number of prior lines of 
systemic treatment (0 or 1 versus two or more), HER-2 status (negative versus positive), 
positivity of CSF cytology at LM diagnosis (negative or equivocal versus positive). A 
sensitivity analysis was also performed by excluding patients with a major protocol violation. 
We used a competing risk approach in order to estimate the treatment effect on the different 
components of the PFS where systemic progression without LM progression and death without 
progression were considered as competing events of LM progression. Cumulative incidence of 
the different events was obtained by the Kalbfleish and Prentice) 17 method and the comparison 
between groups (control, experimental) was done using by the Fine and Gray 18 models, leading 
to the estimate of subdistribution HR (sub-HR).  
Safety analyses were performed on the as-treated population, excluding patients who 
did not receive any treatment. For each category of AE, the proportion of patients having 
experienced an AE of any grade as well as the proportion of patients with severe AE were 
estimated by treatment group and displayed in a butterfly plot. The relative risk of having 
experienced a severe AE in the experimental group versus control was estimated. Details of 
grades per preferred term were tabulated by treatment group. 
Q-TWiST was estimated from randomization until death with a restriction time set at 
18 months. For this analysis, each patient's OS duration was partitioned into three mutually 
exclusive health states: time spent with severe adverse event (grade 3 or 4) before progression 
(TOX), time spent after LM progression (LM-PROG) and time spent without severe adverse 
event before progression (TWiST). The time spent in each state was weighted by a health-state 
utility associated with each state, UTOX=0.5, UTWiST=1 and ULM-PROG=0.5 and summed 



































































































































All randomized patients, for whom baseline measures of quality of life were available, 
were included in the quality of life analysis. For each dimension of the considered QoL 
questionnaire, the time until definitive deterioration of quality of life was compared between 
treatment groups by logrank test and the effect of treatment was estimated by HR of QoL 
deterioration using Cox models. Statistical analyses were done with Stata/SE (version 15·0) 




Accrual period and trial participants 
A total of 74 patients were enrolled from August 2011 to January 2018; 37 patients to 
each group. One patient from the experimental group withdrew consent (Figure 1). Thus 73 
patients represent the ITT population, 67 patients were treated per protocol. Baseline patient 
characteristics were similar between groups, except for mildly heavier pretreatment with 
systemic treatment and radiotherapy in the control group, which, however, had overall better 
performance status and a higher rate of HER-2 positive tumors (Table 1). 
All patients in the experimental group received at least one intrathecal injection (Table 
2). The median number of injections was 5 (range, 1-20), three patients had a dose reduction. 
Cytarabine was administered via lumbar route only in 24 patients, 12 patients received a 
ventricular reservoir. Thirty-six (97%) and 33 (92%) patients in the control and experimental 
groups received at least one dose of systemic treatment (Table 2, Table S9). A second line of 
systemic treatment was administered in 11 patients (five and six in the control and experimental 
groups), for non-LM progression prior to reaching the primary endpoint of LM-related PD. 
Focal radiotherapy was administered in six (16%) and three (8%) patients in the control and 


































































































































group and 23 patients (64%) in the experimental group received further treatment, including 




LM-related clinical improvement was reported in one (3%) and six (17%) patients in 
the control and experimental groups. MRI responses were observed in three (8%) in the control 
and seven (19%) patients in the experimental groups. CSF cytology complete responses were 
observed in five (14%) versus ten (28%) patients. All patients experienced an event, including 
LM progression in 51 patients, 30 and 21 in the control and experimental groups. There was a 
significant reduction of risk of LM progression or death in the experimental arm (HR= 0.61; 
95% CI, 0.38-0.98; P=0.04) in the ITT analysis. Median LM-PFS was 2.2 versus 3.8 months 
in the control and the experimental groups, and 6-month LM-PFS rate was 19% versus 33%. 
The estimated magnitude of treatment effect was larger in the adjusted analysis (HR=0.47; 95% 
CI, 0.27–0.83; P=0.01) (Table 3, Figure 2A). 
All patients had a PFS event. No patient had isolated progression of brain metastases 
without LM progression. In the unadjusted analysis performed on the ITT population, we 
observed a non-significant 34% reduction of risk of overall progression or death (HR=0.66; 
95% CI, 0.41-1.06; P=0.09; Figure 2B), with a median overall PFS of 2.0 versus 2.4 months in 
the control and experimental groups. The treatment effect was significant in the pre-specified 
multivariate analysis (HR=0.54; 95% CI, 0.31-0.95; P=0.03). In the competing risk approach 
(Table S10, Figure S1), the distribution of events differed between the treatment groups: there 
was a significant reduction of LM progression (P=0.01), contrasting with a trend for an excess 


































































































































Overall, 71 patients have died, two patients are alive, 41.8 and 47.2 months after study 
entry, despite having experienced LM progression. Death was attributed to LM-related 
neurological progression in 25 patients (16 and 9 patients), to a combination of neurological 
and extra-neurological disease in 15 patients (7 and 8 patients) (Table 3), and considered not 
directly related to disease progression in 21 patients (8 and 13 patients) (Table S11). Median 
OS was 4.0 months (95% CI 2.2-6.3) in the control and 7.3 months (95% CI 3.9-9.6) in the 
experimental group. Considering the whole survival curve of the ITT population, the unadjusted 
estimate of HR was 0.85 (95% CI, 0.53-1.36, P=0.51; Figure 2C), and the adjusted HR was 
0.60 (95% CI 0.35-1.02, P=0.057) (Table 3).  
In the PP population, median LM-PFS was 2.2 months (95% CI 1.3-3.0) in the control 
versus 4.3 months (95% CI 2.4-7.4) in the experimental group (unadjusted HR=0.52, 95% CI 
0.31–0.85, P=0.009) (Figure S2A). Overall PFS was different, too, in the PP population, with 
2.0 months (95% CI 1.1-2.5) in the control versus 3.1 months (95% CI 2.2-5.7) in the 
experimental group (Figure S2B) (unadjusted HR=0.58, 95% CI 0.35-0.94, P=0.03). Median 
OS was 4.0 months (95% CI 2.2-6.3) versus 7.3 months (unadjusted HR=0.81, 95% CI 3.9-
12.6, P=0.40). Of note, this difference became significant on adjusted analysis (adjusted 
HR=0.55, 95% CI 0.31-0.96, P=0.04) (Figure S2C). Prognostic factors for OS are summarized 
in Table S12. 
 
Safety 
One patient received no study treatment and was not evaluated for safety. Five patients 
died from AE considered related to systemic treatment toxicity before LM progression. One 
control group patient died from gastrointestinal bleeding with severe thrombocytopenia before 
progression, four experimental group patients died from infection. Another control group 


































































































































was no significant difference in the incidence of severe AE, except for more infections in the 
experimental group, further, chemical meningitis was seen in three patients in the experimental 
group (Table S13, Figure 3). 
The estimated mean duration of time spent without severe AE and before LM 
progression (TWiST) was 1.62 months (95% CI, 0.86-2.39) and 1.39 months (95% CI, 0.90-
1.88) in the control and experimental groups. The estimated duration of time spent with severe 
AE (grade 3 or 4) before progression (TOX) was 1.82 months (95% CI, 0.73-29.1) and 4.93 
(95% CI, 2.93-6.93, respectively, leading to an estimated Q-TWiST of 4.22 months (95% CI, 
3.08-5.36) and 5.04 months (95% CI, 3.94-6.14) respectively. The difference was not 
significant (P=0.33) with an absolute Q-TWiST gain of 0.82 months (95% CI, -0.82-2.46) in 
the experimental group compared with the control group (Figure S3). 
 
QoL and performance status 
We observed a trend favoring the experimental group regarding time until definitive 
deterioration for most dimensions of QLQ C-30, QLQ-BN20 and QLQ-C15PAL, with 
significant differences for three dimensions (Tables S14-S17, Figure S4). The ECOG-PS 
decreased over time in both groups (Table S18). No analysis of steroid use was performed 
because of the recommendation of primary steroid prophylaxis after liposomal cytarabine in 




DEPOSEIN is the first randomized trial to show a clinical benefit from intrathecal 


































































































































gain in LM-related PFS when breast cancer patients with newly diagnosed LM received 
intrathecal liposomal cytarabine chemotherapy together with systemic treatment compared with 
systemic treatment alone (Figure 2A). No differences in quality of life were observed between 
groups although patients in the experimental group had more intensive treatment, reflected by 
more CTCAE grade 3 or more infections. Quality of life may even have been maintained longer 
in the experimental group because of prolonged PFS. 
Patient selection remains a challenge in LM trials since the presentation of LM is highly 
variable. A classification into distinct subtypes as developed by the EANO ESMO task force 7 
was not available when DEPOSEIN was initiated. We based inclusion on positive CSF cytology 
in the majority of patients (Table 1), but a combination of typical clinical symptoms or signs 
and typical MRI findings in the absence of positive CSF cytology allowed inclusion, too. 
LM-PFS was chosen as the primary endpoint since intrathecal chemotherapy is a local 
treatment aimed at improving local control in the LM compartment. There was nevertheless 
improved overall PFS in the experimental arm in the adjusted ITT population (Table 3, Figure 
2B), suggesting that adequate coverage of the subarachnoid space sanctuary may affect global 
disease control. Accordingly, in the adjusted ITT population, risk of death was nearly 
significantly reduced in the experimental arm.  
DEPOSEIN has some limitations. It was a small, open label trial, without stratifications, 
leading to imbalances between groups. Control group patients had heavier pretreatment, but 
also more often HER-2-positive tumors, both of which were identified as prognostic factors 
(Table 1). There was major cross-over towards intrathecal therapy at LM progression. The type 
of systemic treatment was not standardized, but left at the discretion of the investigator as LM 
usually occurs in late stage disease when several lines of treatment have already been exhausted. 
There were no validated tools for the determination of response and these still do not exist 19. 


































































































































up and had a priori defined criteria for determination of response. CSF cytology was not 
considered for the determination of LM-PFS for its low sensitivity and risk of misinterpretation, 
a concern that is still valid today 7. Finally, liposomal cytarabine is currently not available, 
indicating that the encouraging results from DEPOSEIN may need to be confirmed with other 
intrathecal agents with superior intrinsic anti-tumor activity. Standard cytarabine for intrathecal 
use is still available for intrathecal use, but would have to be administered twice weekly.  
DEPOSEIN provides a major advance over previous clinical trials conducted in this 
therapeutic area, mostly because these earlier, nevertheless important trials were designed and 
conducted 10-20 years ago, with little statistical power, without challenging the concept of 
intrathecal chemotherapy as such, with one notable exception of a trial that was, however, not 
completed 11 and most importantly including patients with LM from different primary tumors 
which would not be considered state of the art today. Furthermore, future clinical trials on 
intrathecal therapy should consider superior patient selection, e.g., focus on patients with 
molecularly defined types of cancer, with positive CSF cytology and diffuse linear disease 
rather than bulky disease, which may not be reached by intrathecally administered agents. In 
conclusion, DEPOSEIN confirms a role for intrathecal pharmacotherapy in subsets of LM 
patients. New approaches using targeted agents such as trastuzumab for LM from breast cancer 
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Figure 1. CONSORT chart for the DEPOSEIN trial. For the per protocol analysis, we excluded 
six patients: two patients in the control group who did not receive treatment as planned in the 
protocol; four patients in the experimental group, one because she was included although not 
matching the eligibility criteria and three because they did not receive treatment as planned per 
protocol1.  
 
Figure 2. Progression-free survival related to leptomeningeal disease (LM-PFS) (A), overall 
PFS (B) and overall survival (OS) (C) in the ITT population 
 
Figure 3. Butterfly plot of adverse events (related or not) in the two groups by system organ 
class. The panel on the left is a butterfly plot showing the proportion of patients experiencing 
an adverse event coded as related or not to the study treatment, whatever the grade (light blue 
for control group and yellow for experimental group), and a severe adverse event, grade ≥ 3 
(dark blue for control group and orange for experimental group) according to group of 
randomization. The panel on the right displays the relative risk of a severe adverse event in 
patients in the experimental group relative to patients in the control group, with 95% confidence 
interval (CI). The toxicity items were pooled by system organ class. Details of adverse events 












































































































































   
 






















   
 






















   
 






















   
 





















   
 





















Breast cancer history       
Age at breast cancer diagnosis       
Years, median (range) 47.5 (29.7 ; 84.1) 50.9 (30.1 ; 75) 50.2 (29.7 ; 84.1) 
Histology, n (%)        
Invasive ductal carcinoma 23 62% 23 62% 46 63% 
Invasive lobular carcinoma 9 24% 9 25% 18 25% 
Other subtypes 1 5 14% 4 11% 9 12% 
Differentiation, n (%)       
Moderate 9 24% 11 31% 20 27% 
Poor 20 54% 12 33% 32 44% 
Other 1 3% 1 3% 2 3% 
Unknown 7 19% 12 33% 19 26% 
T status per TNM at diagnosis of breast cancer       
1 5 14% 9 25% 14 19% 
2 12 32% 9 25% 21 29% 
3 5 14% 4 11% 9 12% 
4 5 14% 2 6% 7 10% 
X (unknown) 10 27% 12 33% 22 30% 
N status per TNM at diagnosis of breast cancer       
0 6 16% 8 22% 14 19% 
1 11 30% 10 28% 21 29% 
2 5 14% 2 6% 7 10% 
3 2 5% 2 6% 4 5% 
X (unknown) 13 35% 14 39% 27 37% 
M status per TNM at diagnosis of breast cancer       
0 22 59% 21 58% 43 59% 
1 5 14% 8 22% 13 18% 
X (unknown) 10 27% 7 19% 17 23% 
Estrogen receptor status, n (%)       
Negative 11 30% 9 25% 20 27% 
Positive 24 65% 27 75% 51 70% 
Unknown 2 5% 0 0% 2 3% 
Progesterone receptor status, n (%)       
Negative 17 46% 11 31% 28 38% 
Positive 18 49% 24 67% 42 58% 
Unknown 2 5% 1 3% 3 4% 
HER-2 status, n (%)       
Negative 25 68% 30 83% 55 75% 
Positive 9 24% 2 6% 11 15% 
Unknown 3 8% 4 11% 7 10% 
Triple-negative tumor, n (%)       
No 28 76% 29 81% 57 78% 
Yes 7 19% 5 14% 12 16% 


































































































































LM presentation       
Age at LM diagnosis       
Years, median (range) 59 (31 ; 87) 57 (41 ; 76) 57 (31 ; 87) 
BMI classification at LM diagnosis       
Underweight 2 5% 2 6% 4 5% 
Normal range 16 43% 18 50% 34 47% 
Overweight 6 16% 11 31% 17 23% 
Obese 11 30% 5 14% 16 22% 
Unknown 2 5% 0 0% 2 3% 
Systemic therapy before LM diagnosis, n (%) 37 100% 34 94% 71 97% 
Number of lines, Median (range) 3 (1 ; 11) 2 (0 ; 8) 3 (0 ; 11) 
Prior surgery for brain metastases, n (%) 3 8% 2 6% 5 7% 
Prior central nervous system radiotherapy, n (%) 10 27% 5 14% 15 21% 
Focal radiotherapy alone 6 16% 3 8% 9 12% 
Whole brain radiotherapy (+/- focal) 4 11% 2 6% 6 8% 
Neurological symptoms or signs, n (%) 33 89% 34 94% 67 92% 
MRI findings suggestive of LM diagnosis, n (%) 37 100% 34 94% 71 97% 
CSF cytology at LM diagnosis within 14 days prior 
to randomization, n (%) 
      
Positive 29 78% 26 72% 55 75% 
Negative 6 16% 8 22% 14 19% 
Equivocal 2 5% 2 6% 4 5% 
CSF protein (7 missing data)       
g/L, median (range) 0.8 (0.2 ; 7.1) 0.7 (0.3 ; 21.8) 0.8 (0.2 ; 21.8) 
Patient characteristics at LM diagnosis       
Time interval (years) between breast cancer 
diagnosis and LM diagnosis 
      
Years, median (range) 4.5 (0.4 ; 25.4) 7.3 (0.1 ; 24) 4.7 (0.1 ; 25.4) 
Breast cancer manifestations at LM diagnosis       
Brain metastases, n (%) 15 41% 8 22% 23 32% 
Non-CNS metastatic sites, n (%) 35 95% 34 94% 69 95% 
Liver 19 51% 19 53% 38 52% 
Lung/pleura 16 43% 17 47% 33 45% 
Bone / bone marrow 26 70% 30 83% 56 77% 
Cutaneous 6 16% 4 11% 10 14% 
Lymph nodes 14 38% 5 14% 19 26% 
Other 12 32% 8 22% 20 27% 
LM as one of the initial sites of metastases (n, %) 5 14% 4 11% 9 12% 
ECOG-Performance Status at LM diagnosis, n (%)       
0 7 19% 3 8% 10 14% 
1 16 43% 15 42% 31 42% 
2 14 38% 17 47% 31 42% 
4 0 0% 1 3% 1 1% 
Montreal Cognitive Assessment (MoCA)        
Score, median (range) 25 (9 ; 30) 26 (5 ; 30) 26 (5 ; 30) 
Unknown 7  1  8  
Medical Research Council scale at LM diagnosis       


































































































































Light functional neurological disorder, allowing 
useful work 15 41% 14 39% 29 40% 
Moderate functional neurological disorder  10 27% 11 31% 21 29% 
Major functional neurological disorder 1 3% 4 11% 5 7% 
Unknown 0 0% 2 6% 2 3% 
 
1 Other subtypes histology: 4 mixed ductal and lobular, 1 atypical medullary carcinoma, 1 







































































































































Table 2. Study treatment until further progression or end of study, and treatment at first LM 
progression in the ITT population 
 
 
Control group  
(N=37) 
Experimental group  
(N=36) 
Intrathecal liposomal cytarabine until LM progression 
or end of study 
  
Administration of liposomal cytarabine, n (%) 1 (3%)1 36 (100%) 
Duration of treatment, months, median (range) 11.3 3.1 (0.4 ; 31.4) 
Number of injections: median (range) 14 5 (1-20) 
Lumbar route only 0 24 (67%) 
Ventricular route  1 12 (33%) 
Time from randomization to first injection, days (range) 0 0 (0 ; 13) 
Systemic treatment, n (%) 1 until LM progression or 
end of study 
36 (97%) 33 (92%) 
Duration of treatment, months, median (range) 2.4 (0.6 ; 44.8) 3.6 (0.7 ; 18.2) 
Type of systemic treatment  
(sometimes in combination) 
  
Chemotherapy 2 33 33 
Hormonal therapy 1 1 
HER-2 targeted treatment 7 2 
Other targeted treatment 3 1 
Focal CNS radiotherapy, n (%) until LM progression 
or end of study 
(sometimes in combination) 3 
6 (16%) 3 (8%) 
Brain 6 2 
Spine 1 1 
Treatment at further LM progression, n (%) 
(possibly associated) 
30 (81%) 23 (64%) 
Intrathecal therapy 15 2 
Focal radiotherapy 1 2 
Systemic therapy 19 10 
 
1 Two patients in the control group and four patients in the experimental group had a major 
protocol violation. They are excluded from the per protocol population (see Figure 1). 
2 Systemic pharmacotherapy at study entry is detailed in Table S9. 
3 Six patients in the control group received focal radiotherapy: posterior fossa (n=3), meningeal 
nodule at brain level (n=1), cauda equina (n=1), meningeal nodule at brain level and cauda 
equina (n=1); three patients in the experimental group received focal radiotherapy: posterior 


































































































































Table 3. Treatment effect on efficacy outcomes – Intent-to-Treat (ITT) / Per Protocol (PP) 
populations 
 
 ITT population Per Protocol population 1 








 N=37 N=36 N=35 N=32 
Best LM response2 
Clinical     
Improvement 1 (3%) 6 (17%) 1 (3%) 6 (19%) 
Stabilization 30 (81%) 26 (72%) 28 (80%) 24 (75%) 
Deterioration 4 (11%) 4 (11%) 4 (11%) 2 (6%) 
Missing 3 2 (5%) 0 (0%) 2 (6%) 0 (0%) 
Radiological     
PR 3 (8%) 7 (19%) 3 (9%) 7 (22%) 
SD 12 (32%) 20 (56%) 11 (31%) 18 (56%) 
PD 11 (30%) 5 (14%) 11 (31%) 5 (16%) 
Missing or unevaluable 4 11 (30%) 4 (11%) 10 (29%) 2 (6%) 
CSF cytology     
CR 5 (14%) 10 (28%) 4 (11%) 10 (31%) 
SD 22 (59%) 23 (64%) 21 (60%) 21 (66%) 
PD 2 (5%) 0 (0%) 2 (7%) 0 (0%) 
Missing or unevaluable 5 8 (22%) 3 (8%) 8 (23%) 1 (3%) 
LM-related progression-free survival (LM-PFS)  
Number and type of events 37 36 35 32 
- LM-related progression 30 21 29 19 
- Death without LM-related progression 7 15 6 13 
Median LM-PFS (95% CI) 2.2 (1.3-3.1) 3.8 (2.3-5.7) 2.2 (1.3-3.0) 4.3 (2.4-7.4) 
LM-PFS rate (95% CI)     
- at 2 months  54.1 (36.9-68.4)  80.6 (63.5-90.2) 54.3 (36.6-69.0) 90.6 (73.7-96.9) 
- at 4 months 21.6 (10.2-35.8) 50.0 (32.9-64.9) 20.0 (8.8-34.4) 56.3 (37.6-71.3) 
- at 6 months 18.9 (8.3-32.8) 33.3 (18.8-48.6) 17.1 (7.0-31.1) 37.5 (21.3-53.7) 
Unadjusted HR (95% CI) 1 (ref) 0.61 (0.38-0.98) 1 (ref) 0.52 (0.31-0.85) 
P-value  P=0·04  P=0.009 
Adjusted HR (95% CI) 6 1 (ref) 0.47 (0.27-0.83) 1 (ref) 0.41 (0.23-0.74) 
P-value  P=0.01  P=0.003 
Overall progression-free survival (PFS) 
Number and type of first event 37 36 35 32 
- LM progression as first event 27 16 26 13 
- Systemic progression without LM prog. as 
first event 
7 15 6 14 
- Death without reported progression  3 5 3 5 
Median PFS (95% CI) 2.0 (1.3-2.9) 2.4 (2.0-4.4) 2.0 (1.1-2.5) 3.1 (2.2-5.7) 
PFS rate (95% CI)     
- at 2 months  51.4 (34.4-66.0) 69.4 (51.7-81.8) 51.4 (34.0-66.4) 78.1 (59.5-88.9) 
- at 4 months 18.9 (8.3-32.8) 41.7 (25.6-57.0) 17.1 (7.0-31.1) 46.9 (29.2-62.8) 
- at 6 months 13.5 (4.9-26.4) 25.0 (12.4-39.8) 11.4 (3.6-24.2) 28.1 (14.0-44.1) 
Unadjusted HR (95% CI)  1 (ref) 0.66 (0.41-1.06) 1 (ref) 0.58 (0.35-0.94) 
P-value  P=0.09  P=0.03 
Adjusted HR (95% CI) 6 1 (ref) 0.54 (0.31-0.95) 1 (ref) 0.47 (0.26-0.83) 


































































































































 ITT population Per Protocol population 1 








 N=37 N=36 N=35 N=32 
Overall survival (OS) 
Number and type of deaths 35 36 33 32 
- Death related to neurological 
progression 
16 9 15 7 
- Death related to extra-CNS progression 4 6 3 6 
- Death related to combined progression 7 8 7 8 
- Study treatment (systemic treatment) 
related death 7 
2 4 2 4 
- Other 7 2 4 2 4 
- Unknown  4 5 4 3 
Median OS (95% CI) 4.0 (2.2-6.3) 7.3 (3.9-9.6) 4.0 (2.2-6.3) 7.3 (3.9-12.6) 
OS rate (95% CI)     
- at 2 months  70.3 (52.8-82.3) 86.1 (69.8-94.0) 68.6 (50.5-81.2) 93.8 (77.3-98.4) 
- at 4 months 51.4 (34.4-66.0) 63.9 (46.1-77.2) 51.4 (34.0-66.4) 68.8 (49.7-81.8) 
- at 6 months 40.5 (24.9-55.7) 55.6 (38.1-69.9) 40.0 (24.0-55.5) 59.4 (40.5-74.0) 
Unadjusted HR (95% CI)  1 (ref) 0.85 (0.53 -1.36) 1 (ref) 0.81 (0.50-1.32) 
P-value  P=0.51  P=0.40 
Adjusted HR (95% CI) 6 1 (ref) 0.60 (0.35-1.02) 1 (ref) 0.55 (0.31-0.96) 
P-value  P=0.057  P=0.04 
 
CI: confidence interval, CNS: central nervous system, CR: complete response, HR: Hazard 
Ratio, LM: leptomeningeal metastases, PFS: progression-free survival, OS: overall survival, 
PD: progressive disease, PR: partial response, ref: reference, SD: stable disease 
 
1 Per protocol population, excluding 2 and 4 patients in the control arm and the experimental 
arm, respectively, who had a major protocol violation (see Figure 1). 
2 Clinical data were collected every 14±2 days for 2 months then every 28 days +/- 5 days, 
CSF cytology data were collected every 14±2 days in the experimental group and every 28±5 
days in the control group for 2 months and then every 28 days +/- 5 days for the 2 groups; 
cerebrospinal MRI was performed every 2 months (see Table S4) 
3 Information about best clinical response is missing for 3 patients who went off study early 
(<2 months) 
4 Information about best radiological response is missing for 15 patients who had an early 


































































































































5 Information about best cytological response is missing for 11 patients who went out of study 
early (<2 months), mainly due to clinical progression or death. 
6 Model adjusted for ECOG-PS at LM diagnosis (0 vs. 1 vs. 2+), number of prior lines of 
systemic treatment (0-1 vs. 2+), HER-2 status at diagnosis (positive vs. negative, excluding 7 
cases with missing data) and positivity of CSF cytology at LM diagnosis (positive vs. 
negative or equivocal)  
7 The deaths reported as first event without prior progression, as well as all other deaths not 
classified as related to disease progression are detailed in Table S11 
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